221b Foundation and LogicInk have partnered to develop an instrument-free, non-invasive, saliva-based Covid-19 diagnostic biosensor. The diagnostic device will integrate Sherlock Biosciences’ CRISPR diagnostic technology with LogicInk’s DNA nanotechnology proprietary platform. It is expected to enable people to self-administer and detect the presence of SARS-CoV-2 RNA.
FluroTest Diagnostics Systems has collaborated with Total Testing Solutions to launch a first-of-its-kind pilot programme to introduce a high-volume Covid-19 testing system in California. The companies intend to move the test from the LA-based screening facilities, which are utilising it for research only purposes to commercial scale use, subject to receiving approval from the US Food and Drug Administration (FDA).
AXIM Biotechnologies has introduced a new ELISA test that measures levels of immune protection against six common variants of the SARS-CoV-2 virus in less than two hours. The test may also provide insights about the efficiency of vaccines against SARS-CoV-2 variants to vaccine developers.